Evidence map›Paper›PMID 34233449›Full record

ArticleHaematologica2021

Aurora A kinase as a target for therapy in

Jessica Leonard, Joelle Sj Wolf, Michelle Degnin, Christopher A Eide, Dorian LaTocha, Kyle Lenz, Beth Wilmot, Charles G Mullighan, Mignon Loh, Stephen P Hunger and 4 more

Open access · goldAbstract readLetter
In one paragraph

Article in Haematologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. International Consensus Classification of acute lymphoblastic leukemia/lymphoma.Virchows Archiv : an international journal of pathology · 2023
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Jessica LeonardDivision of Hematology and Medical Oncology, Department of Medicine and OHSU Knight Cancer Institute. OHSU, Portland, Oregon.
Joelle Sj WolfDivision of Hematology and Oncology, Department of Pediatrics and OHSU Knight Cancer Institute. OHSU, Portland, Oregon.
Michelle DegninDivision of Hematology and Medical Oncology, Department of Medicine and OHSU Knight Cancer Institute. OHSU, Portland, Oregon.
Christopher A EideDivision of Hematology and Medical Oncology, Department of Medicine and OHSU Knight Cancer Institute. OHSU, Portland, Oregon.
Dorian LaTochaDivision of Hematology and Medical Oncology, Department of Medicine and OHSU Knight Cancer Institute. OHSU, Portland, Oregon.
Kyle LenzDivision of Hematology and Oncology, Department of Pediatrics and OHSU Knight Cancer Institute. OHSU, Portland, Oregon.
Beth WilmotDivision of Bioinformatics and Computational Biology, Department of Medical Informatics and Clinical Epidemiology, and OHSU Knight Cancer Institute, OHSU, Portland, Oregon.
Charles G MullighanDepartment of Pathology, St Jude Children's Research Hospital and University of Tennessee Health Science Center, Memphis, TN 38105.
Mignon LohDepartment of Pediatrics, Benioff Children's Hospital, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
Stephen P HungerDepartment of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Children's Hospital of Philadelphia.
Brian J DrukerDivision of Hematology and Medical Oncology, Department of Medicine and OHSU Knight Cancer Institute. OHSU, Portland, Oregon, USA; Investigator, Howard Hughes Medical Institute.
Marc M LoriauxDepartment of Pathology and OHSU Knight Cancer Institute. OHSU, Portland, Oregon.
Jeffrey W TynerDivision of Hematology and Medical Oncology, Department of Medicine and OHSU Knight Cancer Institute. OHSU, Portland, Oregon, USA; Department of Cell, Molecular, and Cancer Biology, and OHSU Knight Cancer Institute, OHSU, Portland, Oregon.
Bill H ChangDivision of Hematology and Oncology, Department of Pediatrics and OHSU Knight Cancer Institute. OHSU, Portland, Oregon.
OHSU Knight Cancer InstituteHoward Hughes Medical Institute · USUCSF Benioff Children's Hospital · USUniversity of Pennsylvania · USUniversity of Tennessee Health Science Center · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
Translating genomic discoveries to improved outcomes for high risk acute leukemiaR35CA197695 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Charles G Mullighan · 2017 to 2026
$11.4M
NCI NIH HHS P30 CA021765NCI NIH HHS R35 CA197695
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Aurora Kinase APrecursor Cell Lymphoblastic Leukemia-LymphomaBasic Helix-Loop-Helix ProteinsHumansOncogene Proteins, FusionTranslocation, GeneticAurora Kinase ABasic Helix-Loop-Helix ProteinsOncogene Proteins, FusionTCF3-HLF fusion protein, humanTCF3 protein, human

Identifiers

PMID34233449
PMCPMC8561293
OpenAlexW3180272853

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.